RxDoctor Payments Data

Julie Spivack, MD

Gastroenterology · Fairfield, CTNPI 1316939226

Payments from drug & device makers

$11,675in general payments, 2019–2025

Across 647 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$797
  • Bristol Myers Squibb$700
  • Pfizer$633
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$11,644100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,675 in reported general payments places this provider in the 75th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$72,184
Medicare patients
297
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase14$58,936
LinzessLinaclotide40$46,668
XifaxanRifaximin11$25,707
VemlidyTenofovir Alafenamide13$16,811
Mesalamine40$11,477
Dexlansoprazole DrDexlansoprazole22$10,480
Ursodiol34$9,789
SutabSod Sulf/Pot Chloride/Mag Sulf26$4,212
Pantoprazole Sodium295$3,959
Esomeprazole Magnesium80$2,632
Rabeprazole Sodium40$1,910
Famotidine117$1,669
Omeprazole100$1,137
Lansoprazole36$1,000
Dicyclomine Hcl27$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,627$105,60454 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,398$25,70711 claims
GileadVemlidy$492$16,81113 claims
Braintree Laboratories, Inc.Sutab$14$4,21226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →